<VariationArchive RecordType="classified" VariationID="30369" VariationName="NG_007094.1:g.(45669_45717)_(52301_52349)del" VariationType="Deletion" Accession="VCV000030369" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-09-03" DateCreated="2017-07-22" MostRecentSubmission="2017-07-22">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="39326" VariationID="30369">
      <GeneList>
        <Gene Symbol="PLA2G6" FullName="phospholipase A2 group VI" GeneID="8398" HGNC_ID="HGNC:9039" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="38111495" stop="38181830" display_start="38111495" display_stop="38181830" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="38507501" stop="38577835" display_start="38507501" display_stop="38577835" Strand="-" />
          </Location>
          <OMIM>603604</OMIM>
        </Gene>
      </GeneList>
      <Name>NG_007094.1:g.(45669_45717)_(52301_52349)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" outerStart="38134406" innerStart="38134454" innerStop="38141038" outerStop="38141086" display_start="38134406" display_stop="38141086" variantLength="6681" Strand="-" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" outerStart="38530413" innerStart="38530461" innerStop="38537045" outerStop="38537093" display_start="38530413" display_stop="38537093" variantLength="6585" />
      </Location>
      <OtherNameList>
        <Name>6.6-KB DEL</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007094.1" sequenceAccession="NG_007094" sequenceVersion="1" change="g.(45669_45717)_(52301_52349)del">
            <Expression>NG_007094.1:g.(45669_45717)_(52301_52349)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.(38134406_38134454)_(38141038_38141086)del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.(38134406_38134454)_(38141038_38141086)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.(38530413_38530461)_(38537045_38537093)del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.(38530413_38530461)_(38537045_38537093)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 20584031 Fig. 2c to determine the location of this allele on the current reference sequence.</Comment>
      <Comment DataSource="NCBI curation" Type="public">6.6-kb genomic deletion beginning in intron 4 and ending in intron 6 of PLA2G6, resulting in deletion of exons 5 and 6 from the protein product.</Comment>
      <Comment DataSource="NCBI curation" Type="LocationOnGenomeAndProductNotAligned">Deletion occurs between two repeated Alu sequences in intron 4 and 6 results in in deletion of exons 5 and 6 from the protein product.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NG_007094.1:g.(45669_45717)_(52301_52349)del AND Infantile neuroaxonal dystrophy" Accession="RCV000023317" Version="4">
        <ClassifiedConditionList TraitSetID="1718">
          <ClassifiedCondition DB="MedGen" ID="C0270724">Infantile neuroaxonal dystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2010-11-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2010-11-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-07-22" MostRecentSubmission="2017-07-22">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20584031</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5628" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0003" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0001" DB="OMIM" />
                <XRef Type="Allelic variant" ID="603604.0007" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Seitelberger disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Infantile neuroaxonal dystrophy</ElementValue>
                <XRef ID="Neuroaxonal+dystrophy%2C+infantile/5159" DB="Genetic Alliance" />
                <XRef ID="52713000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Infantile neuroaxonal dystrophy 1</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">INAD</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">INAD1</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA2A</ElementValue>
                <XRef Type="MIM" ID="256600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">PLA2G6-Associated Neurodegeneration</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PLA2G6-associated neurodegeneration (PLAN) comprises a continuum of three phenotypes with overlapping clinical and radiologic features: Infantile neuroaxonal dystrophy (INAD). Atypical neuroaxonal dystrophy (atypical NAD). PLA2G6-related dystonia-parkinsonism. INAD usually begins between ages six months and three years with psychomotor regression or delay, hypotonia, and progressive spastic tetraparesis. Many affected children never learn to walk or lose the ability shortly after attaining it. Strabismus, nystagmus, and optic atrophy are common. Disease progression is rapid, resulting in severe spasticity, progressive cognitive decline, and visual impairment. Many affected children do not survive beyond their first decade. Atypical NAD shows more phenotypic variability than INAD. In general, onset is in early childhood but can be as late as the end of the second decade. The presenting signs may be gait instability, ataxia, or speech delay and autistic features, which are sometimes the only evidence of disease for a year or more. Strabismus, nystagmus, and optic atrophy are common. Neuropsychiatric disturbances including impulsivity, poor attention span, hyperactivity, and emotional lability are also common. The course is fairly stable during early childhood and resembles static encephalopathy but is followed by neurologic deterioration between ages seven and 12 years. PLA2G6-related dystonia-parkinsonism has a variable age of onset, but most individuals present in early adulthood with gait disturbance or neuropsychiatric changes. Affected individuals consistently develop dystonia and parkinsonism (which may be accompanied by rapid cognitive decline) in their late teens to early twenties. Dystonia is most common in the hands and feet but may be more generalized. The most common features of parkinsonism in these individuals are bradykinesia, resting tremor, rigidity, and postural instability.</Attribute>
                <XRef ID="NBK1675" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301718</ID>
                <ID Source="BookShelf">NBK1675</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="35069" DB="Orphanet" />
              <XRef ID="C0270724" DB="MedGen" />
              <XRef ID="MONDO:0024457" DB="MONDO" />
              <XRef Type="MIM" ID="256600" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="49864" SubmissionDate="2017-07-19" DateLastUpdated="2017-07-22" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603604.0014_NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A" title="PLA2G6, 6.6-KB DEL_NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A" />
        <ClinVarAccession Accession="SCV000044608" DateUpdated="2017-07-22" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2010-11-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with infantile neuroaxonal dystrophy (NBIA2A; 256600), Tonelli et al. (2010) identified compound heterozygosity for 2 mutations in the PLA2G6 gene: a 6.6-kb deletion from intron 4 to 6, resulting in an in-frame deletion and removal of exons 5 and 6 and a large portion of the ankyrin repeats motif, and a 109C-T transition in exon 2 resulting in an arg37-to-ter (R37X; 603604.0015) substitution. Analysis of the deletion junction in the first mutation showed that both breakpoints occurred within AluY sequences, suggesting that the deletion was likely mediated by nonallelic homologous recombination (NAHR). The mutations were predicted to result in an almost complete lack of enzyme activity, although a gain of function could not be excluded. The patient had a severe and rapidly progressive disease course, with onset before age 12 months, hypotonia, severe developmental delay with mental retardation, and no eye contact. Spastic tetraparesis developed by age 18 months. Skin biopsy showed axonal spheroids. Although brain iron accumulation was not present, MRI at age 20 months showed hyperintensities on T2-weighted imaging in the caudate and putamen, suggesting an early degeneration process. Brain MRI at age 3 years showed cerebellar cortical atrophy.</Attribute>
              <Citation>
                <ID Source="PubMed">20584031</ID>
              </Citation>
              <XRef DB="OMIM" ID="256600" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PLA2G6" />
          </GeneList>
          <Name>PLA2G6, 6.6-KB DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">6.6-KB DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603604.0014" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="49864" TraitType="Disease" MappingType="Name" MappingValue="NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A" MappingRef="Preferred">
        <MedGen CUI="C0270724" Name="Infantile neuroaxonal dystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

